Login

If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

News

Home > News

Please scroll down to find news and features relating to the NOVELTY study as we embark on this journey of discovery, or click on the image to the right for extra news for investigators and AstraZeneca Medical employees.

Extra news for investigators and AstraZeneca Medical employees

Read More

News

9th September, 2023

NOVELTY at ERS 2023

Read More

11th June, 2023

Burden of uncontrolled severe asthma manuscript published

Read More

23rd May, 2023

NOVELTY cluster analysis manuscript published

Read More

30th March, 2021

NOVELTY baseline characteristics manuscript published

Now published in the European Respiratory Journal: baseline characteristics from the NOVELTY study, with accompanying video summary.
Read More

26th February, 2021

Respiratory Symptoms Questionnaire manuscript published

Now published in ERJ Open Research: validation of Respiratory Symptoms Questionnaire.
Read More

26th February, 2021

NOVELTY at ISPOR Europe 2020

The humanistic burden of mild asthma – ePoster presented at the virtual ISPOR Europe Conference 2020.
Read More

21st December, 2020

NOVELTY at ERS 2020

Six NOVELTY ePosters were presented at the virtual ERS Congress 2020, and the related abstracts have now been published online.
Read More

17th November, 2020

Observational studies review published

We are pleased to announce that ‘Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design’ has been published.
Read More

14th July, 2020

NOVELTY at ATS 2020

The COVID-19 pandemic is a key transformative event in the lifetime of the NOVELTY study ...
Read More

3rd June, 2020

The COVID-19 pandemic and NOVELTY

The COVID-19 pandemic is a key transformative event in the lifetime of the NOVELTY study. The NOVELTY study provides a unique opportunity to better understand the risk and outcomes of COVID-19 infection in patients with asthma and/or COPD.
Read More

18th March, 2020

An update on NOVELTY governance: the NOVELTY Scientific Community

The NOVELTY Scientific Community was established at the annual face-to-face meeting on 22 January 2020. This new structure represents an evolution in the NOVELTY scientific strategy, setting and delivery, bringing together the separate bodies of the Scientific Committee, the National Principal Investigators and the AstraZeneca science and evidence leads.
Read More

10th December, 2019

Severe obstructive lung disease review article published

We are pleased to announce that a review article entitled ‘Defining severe obstructive lung disease in the biologic era: an endotype-based approach’ has been published in the European Respiratory Journal.
Read More

7th April, 2016

A message from the NOVELTY Scientific Committee

We are very pleased to announce the launch of the NOVELTY study, and are enthusiastic to be working with physicians and study centres around the world to increase our knowledge of obstructive lung disease on a global, local and individual patient level.
Read More
19 PARTICIPATING COUNTRIESa
~12,000 ENROLLED PATIENTSa
84% OF PATIENTS HAVE SPIROMETRY DATAb

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study